Fertility-sparing surgery in children and adolescents with borderline ovarian tumors: a retrospective study.

IF 3.8 3区医学 Q1 REPRODUCTIVE BIOLOGY Journal of Ovarian Research Pub Date : 2024-05-08 DOI:10.1186/s13048-024-01409-0

Jiayuan Zhao, Dan Wang, Ruojiao Wang, Yonglan He, Congwei Jia, Lingya Pan, Shuiqing Ma, Ming Wu, Weidi Wang, Xinghan Cheng, Junjun Yang, Yang Xiang

{"title":"Fertility-sparing surgery in children and adolescents with borderline ovarian tumors: a retrospective study.","authors":"Jiayuan Zhao, Dan Wang, Ruojiao Wang, Yonglan He, Congwei Jia, Lingya Pan, Shuiqing Ma, Ming Wu, Weidi Wang, Xinghan Cheng, Junjun Yang, Yang Xiang","doi":"10.1186/s13048-024-01409-0","DOIUrl":null,"url":null,"abstract":"Objective: To describe the characteristics of children and adolescents with borderline ovarian tumors (BOTs) and evaluate the efficacy and safety of fertility-sparing surgery (FSS) in these patients.Methods: Patients with BOTs younger than 20 years who underwent FSS were included in this study.Results: A total of 34 patients were included, with a median patient age of 17 (range, 3-19) years; 97.1% (33/34) of cases occurred after menarche. Of the patients, 82.4% had mucinous borderline tumors (MBOTs), 14.7% had serous borderline tumors (SBOTs), and 2.9% had seromucinous borderline tumor (SMBOT). The median tumor size was 20.4 (range, 8-40)cm. All patients were at International Federation of Gynecology and Obstetrics stage I and all underwent FSS: cystectomy (unilateral ovarian cystectomy, UC, 14/34, 41.2% and bilateral ovarian cystectomy, BC, 1/34, 2.9%), unilateral salpingo-oophorectomy (USO; 18/34; 52.9%), or USO + contralateral ovarian cystectomy (1/34; 2.9%). The median follow-up time was 65 (range, 10-148) months. Recurrence was experienced by 10 of the 34 patients (29.4%). One patient with SBOT experienced progression to low-grade serous carcinoma after the third relapse. Two patients had a total of four pregnancies, resulting in three live births. The recurrence rate of UC was significantly higher in MBOTs than in USO (p = 0.005). The 5-year disease-free survival rate was 67.1%, and the 5-year overall survival rate was 100%.Conclusions: Fertility-sparing surgery is feasible and safe for children and adolescents with BOTs. For patients with MBOTs, USO is recommended to lower the risk of recurrence.","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":null,"pages":null},"PeriodicalIF":3.8000,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11077773/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ovarian Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13048-024-01409-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"REPRODUCTIVE BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To describe the characteristics of children and adolescents with borderline ovarian tumors (BOTs) and evaluate the efficacy and safety of fertility-sparing surgery (FSS) in these patients.

Methods: Patients with BOTs younger than 20 years who underwent FSS were included in this study.

Results: A total of 34 patients were included, with a median patient age of 17 (range, 3-19) years; 97.1% (33/34) of cases occurred after menarche. Of the patients, 82.4% had mucinous borderline tumors (MBOTs), 14.7% had serous borderline tumors (SBOTs), and 2.9% had seromucinous borderline tumor (SMBOT). The median tumor size was 20.4 (range, 8-40)cm. All patients were at International Federation of Gynecology and Obstetrics stage I and all underwent FSS: cystectomy (unilateral ovarian cystectomy, UC, 14/34, 41.2% and bilateral ovarian cystectomy, BC, 1/34, 2.9%), unilateral salpingo-oophorectomy (USO; 18/34; 52.9%), or USO + contralateral ovarian cystectomy (1/34; 2.9%). The median follow-up time was 65 (range, 10-148) months. Recurrence was experienced by 10 of the 34 patients (29.4%). One patient with SBOT experienced progression to low-grade serous carcinoma after the third relapse. Two patients had a total of four pregnancies, resulting in three live births. The recurrence rate of UC was significantly higher in MBOTs than in USO (p = 0.005). The 5-year disease-free survival rate was 67.1%, and the 5-year overall survival rate was 100%.

Conclusions: Fertility-sparing surgery is feasible and safe for children and adolescents with BOTs. For patients with MBOTs, USO is recommended to lower the risk of recurrence.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

边缘性卵巢肿瘤儿童和青少年的保胎手术：一项回顾性研究。

目的描述患有边缘性卵巢肿瘤（BOTs）的儿童和青少年的特征，并评估保胎手术（FSS）对这些患者的有效性和安全性：方法：本研究纳入了年龄小于20岁、接受保胎手术的BOT患者：结果：共纳入 34 例患者，中位年龄为 17 岁（3-19 岁）；97.1%（33/34）的病例发生在月经初潮之后。其中，82.4%的患者患有粘液性边界肿瘤（MBOT），14.7%的患者患有浆液性边界肿瘤（SBOT），2.9%的患者患有血清粘液性边界肿瘤（SMBOT）。肿瘤大小的中位数为 20.4 厘米（8-40 厘米）。所有患者均处于国际妇产科联盟 I 期，均接受了 FSS：囊肿切除术（单侧卵巢囊肿切除术，UC，14/34，41.2%；双侧卵巢囊肿切除术，BC，1/34，2.9%）、单侧输卵管卵巢切除术（USO；18/34；52.9%）或 USO + 对侧卵巢囊肿切除术（1/34；2.9%）。中位随访时间为 65 个月（10-148 个月）。34例患者中有10例（29.4%）复发。一名 SBOT 患者在第三次复发后进展为低级别浆液性癌。两名患者共怀孕四次，其中三次为活产。MBOT的UC复发率明显高于USO（P = 0.005）。5年无病生存率为67.1%，5年总生存率为100%：结论：对于患有BOT的儿童和青少年来说，保胎手术是可行且安全的。结论：对于患有BOT的儿童和青少年来说，保胎手术是可行且安全的。对于患有MBOT的患者，建议进行USO手术以降低复发风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Ovarian Research REPRODUCTIVE BIOLOGY-

CiteScore

6.20

自引率

2.50%

发文量

125

审稿时长

>12 weeks

期刊介绍： Journal of Ovarian Research is an open access, peer reviewed, online journal that aims to provide a forum for high-quality basic and clinical research on ovarian function, abnormalities, and cancer. The journal focuses on research that provides new insights into ovarian functions as well as prevention and treatment of diseases afflicting the organ. Topical areas include, but are not restricted to: Ovary development, hormone secretion and regulation Follicle growth and ovulation Infertility and Polycystic ovarian syndrome Regulation of pituitary and other biological functions by ovarian hormones Ovarian cancer, its prevention, diagnosis and treatment Drug development and screening Role of stem cells in ovary development and function.